Thursday, Angel Biotechnology Holdings Plc (ABH.L) said it is signing a contract with ReNeuron Group Plc. The contract is to perform work to further develop and manufacture clinical-grade lots of a second-generation formulation of ReNeuron's lead CTX stem cell line, for subsequent pre-clinical and clinical applications. The value of the contract was not disclosed, the company said.
"As ReNeuron's manufacturing partner, Angel will be manufacturing the stem cell clinical product for their previously announced first-in-man Phase I clinical trial for stroke. We are very pleased to have been chosen by ReNeuron to further develop and manufacture the second generation formulation of their CTX neural stem cell line for subsequent pre-clinical and clinical applications. Provision of the highest quality support for such advanced biological therapies is Angel's core competence and this contract firmly places Angel in the vanguard of this important and exciting development in medicinal therapy," said Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings Plc.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.